Drug Profile
Lidocaine transdermal patch - Scilex Holding
Alternative Names: Lidocaine 1.8% patch - Scilex Holding; Lidocaine 5.4% patch - Scilex Holding; Lidocaine topical system - Scilex Holding; Lidocaine topical system 1.8% - Scilex Holding; Lidocaine topical system 5.4% - Scilex Holding; SP-103; ZTlidoLatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Scilex Pharmaceuticals
- Developer Scilex Holding; Scilex Pharmaceuticals
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Postherpetic neuralgia
- Phase II Back pain
Most Recent Events
- 20 Feb 2024 Scilex Holding plans a phase III trial for back pain in in 2024
- 08 Jan 2024 Scilex Holding announces intention to submit marketing authorization application for Postherpetic neuralgia in world (except USA) in 2024
- 17 Nov 2023 Scilex Pharmaceuticals has patent protection for lidocaine transdermal patch in the USA